Abstract
Background: Platinum-based therapy (PL) remains the standard of care in MPM, despite encouraging emerging data from immunotherapy (IO) trials. Recently, prognostic MPM clusters with potential implications for targeted-treatments were identified by multiplatform profiling but we are still far from translating these data in therapeutic opportunities for pts. In this scenario, we are leading an international multicenter project on new biomarkers in MPM.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
